WS #14692
The consumer discretionary sector is showing signs of strain as Darden Restaurants (DRI) missed Q1 EPS estimates and Starbucks announced the closure of underperforming North American locations. Combined with BofA trimming General Mills' price target due to inflationary cost pressures, these signals suggest that consumer spending is becoming more fragile, potentially limiting revenue growth for retail and hospitality stocks in the coming quarters. Eli Lilly (LLY) received FDA approval for Onswik, a once-weekly basal insulin for Type 2 diabetes, expanding its dominant pipeline. Merck (MRK) reported that its remigromig met the primary endpoint in a diabetic macular edema trial. These developments reinforce the defensive quality of large-cap healthcare stocks, providing a hedge against the broader tech selloff driven by rising yields.
Consumer Discretionary Pressure
The consumer discretionary sector is showing signs of strain as Darden Restaurants (DRI) missed Q1 EPS estimates and Starbucks announced the closure of underperforming North American locations. Combined with BofA trimming General Mills' price target due to inflationary cost pressures, these signals suggest that consumer spending is becoming more fragile, potentially limiting revenue growth for retail and hospitality stocks in the coming quarters.
Eli Lilly (LLY) received FDA approval for Onswik, a once-weekly basal insulin for Type 2 diabetes, expanding its dominant pipeline. Merck (MRK) reported that its remigromig met the primary endpoint in a diabetic macular edema trial. These developments reinforce the defensive quality of large-cap healthcare stocks, providing a hedge against the broader tech selloff driven by rising yields.